AAGH
America Great Health0.0001
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.12MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
CFO resigns; CEO takes interim role
America Great Health accepted CFO Quinn Chen's resignation for personal reasons, effective June 30, 2025—no disagreements or operational issues noted. CEO Mike Wang steps in as interim CFO during the board's search for a replacement. Smooth transition. Leadership shift tests continuity amid the wait.
10-Q
Q3 FY2025 results
America Great Health posted Q3 sales of $56.1K, down 40% y/y from $94K yet lifting 9M revenue 44% y/y to $287K on new products while gross margins held firm. Operating loss narrowed to $85K from $134K y/y, but net loss widened to $158K versus $229K as interest expense bit harder at $73K. Cash dipped to $36.9K amid $60K 9M operating burn, propped by related-party advances and $2.1M total debt; free cash flow not disclosed in the 10-Q. Shareholders' deficit hit $5.7M. Weak controls persist.
10-Q
Q2 FY2025 results
America Great Health posted Q2 sales of $90.9K, flat y/y from $91.2K but up sharply q/q amid new product launches, driving six-month revenue to $231.1K (+120% y/y). Gross margins held firm near 91%, yet operating loss narrowed to $120.5K (-22% y/y) while net loss hit $193.7K, widened by $73.2K interest expense versus operating shortfall. Cash dwindled to $36K after $6.8K operating outflow, propped by related-party advances amid $5.9M total debt at 16-20% rates. Losses burn fast. Controls falter without audit oversight.
10-Q
Q1 FY2025 results
America Great Health posted Q1 FY2025 sales of $140K, up sharply from $14K y/y, with gross profit hitting $129K on new product launches, yet operating expenses climbed to $200K from $89K y/y, driving an operating loss of $71K (better than $75K y/y). Net loss narrowed to $147K from $157K y/y, as interest expense eased slightly, though the gap from operating loss stems from $76K interest. Cash dipped to $49K amid $96K operating burn, offset by $88K financing; total debt exceeds $2.5M with short-term loans at up to 316% rates and long-term at 20%. Shareholders' deficit widened to $5.4M. Weak controls persist.
10-K
FY2024 results
America Great Health posted FY2024 revenue of $294,670, up from $204,308 in FY2023, with gross profit steady at ~$169k despite COGS jumping to $124,920 on higher volume; yet operating expenses surged 44% to $952,450 on payroll and professional costs, driving net loss to $1.2M from $777k. No quarterly breakdowns disclosed, so momentum stays murky. Cash held flat at $55k, propped by $970k related-party advances against $616k operating burn. Auditors disclaimed opinion over revenue proof gaps. Shareholders' deficit widened to $5.3M. Weak internal controls threaten reporting.
AFJK
Aimei Health Technology Co., Lt
26.96-3.55
AGL
agilon health, inc.
0.67+0.01
AGTX
Agentix Corp.
0.04+0.00
AIBT
Aibotics Inc.
0.00+0.00
GWLL
GOLDENWELL BIOTECH INC
3.00+0.00
IMA
ImageneBio, Inc.
6.25+0.08
NAGE
Niagen Bioscience, Inc.
6.34-0.03
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
RMTG
Regenerative Medical Technology
0.04+0.00
WHWK
Whitehawk Therapeutics, Inc.
2.40+0.04